XTalks

NOVEMBER 4, 2024

Cure Research: Moving Toward an Insulin-Free Future JDRF is focused on funding research that is accelerating the development of new treatments for people with T1D — for all ages and stages. “Our before people need insulin therapy), so that it’s possible to intervene with therapies that can stop clinical disease before it starts.”

Insulin 108

Insulin Research Medicine Doctors 108

Pharmaceutical Technology

JANUARY 10, 2023

There are multiple drugs in the pipeline, predominantly me-too and biosimilar therapies, with a significant number developed in the emerging markets of India and China by domestic pharmaceutical companies for their own rapidly growing markets. billion in sales in 2019, increasing to $136.2

Insulin 130

Insulin Marketing Sales Compliance 130

Medical Xpress

DECEMBER 12, 2022

WEHI researchers in Melbourne have answered a 100-year-old question in diabetes research: can a molecule different to insulin have the same effect? The findings provide important insights for the future development of an oral insulin pill.

Insulin 102

Insulin Research Development 102

pharmaphorum

DECEMBER 7, 2023

Medtech giant Medtronic has decided not to go ahead with a planned acquisition of EOFlow, a developer of patch-based insulin pumps, saying that there have been “multiple breaches” of their takeover agreement.

Insulin 110

Insulin Development 110

BioSpace

AUGUST 19, 2020

Researchers from the Salk Institute took a major step forward in developing a new insulin-producing pancreatic cell cluster as a potential treatment for type 1 diabetes patients.

Development 136

Development Insulin Research 136

XTalks

OCTOBER 28, 2024

Diabetes, a chronic condition marked by high blood glucose levels due to insulin issues, brings complications like heart disease, stroke, neuropathy and diabetic foot ulcers. Abbot also joined Medtronic to pair its sensors with the latter’s automated insulin delivery (AID) systems. million undiagnosed and 115.9

Insulin 105

Insulin FDA Approval Marketing Doctors 105

pharmaphorum

JULY 14, 2021

Eli Lilly bought a stake in Protomer Technologies and its glucose-sensing insulin platform last year, and it must like what it has seen in the programme since then – it has just agreed to buy the company outright. . It was also responsible for the first recombinant insulin product – Humulin – which launched in 1982 and remains on sale.

Insulin 98

Insulin Protein Production Development 98

Pharmaceutical Technology

JUNE 30, 2023

(Glucagon + insulin human)is under clinical development by Abvance Therapeutics and currently in Phase I for Hypoglycemia.

Insulin 100

Insulin Clinical Development Development 100

XTalks

JULY 3, 2023

The treatment is derived from deceased donor pancreatic cells and is indicated for patients who are unable to achieve average blood glucose levels (glycated hemoglobin) with daily insulin injections or with continuous infusion through a pump because of repeated episodes of severe hypoglycemia (low blood sugar).

Insulin 98

Insulin Gene Therapy Gene Regulation 98

BioPharma Reporter

NOVEMBER 21, 2022

Oramed Pharmaceuticals, a company focused on the development of oral drug delivery platforms, has signed an exclusive commercial distribution agreement for the Republic of Korea with local player, Medicox Co Ltd, in relation to its oral insulin candidate.

Insulin 95

Insulin Drug Delivery Development Drugs 95

Pharmaceutical Technology

FEBRUARY 21, 2025

Glucagon-like peptide-1 receptor agonists (GLP-1RAs), originally developed for treating diabetes, work by stimulating insulin secretion and suppressing glucagon release, thereby helping regulate blood sugar.

Insulin 162

Insulin Regulation Development 162

Pharmaceutical Technology

FEBRUARY 24, 2023

(LAI-287 + semaglutide) is under clinical development by Novo Nordisk and currently in Phase III for Type 2 Diabetes. GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data.

Insulin 182

Insulin Hormones Drugs Clinical Trials 182

XTalks

SEPTEMBER 23, 2020

Being hailed as the world’s shortest and thinnest needle for insulin injection, Droplet Micron has recently been introduced into the pen needle market by HTL (High Tech Lab)-STREFA, Inc. These are important feature innovations for those that depend on insulin injections. The new and innovative needle measures at just 34G x 3.5mm.

Insulin 98

Insulin Marketing Drug Delivery Compliance 98

BioPharma Reporter

MAY 3, 2023

Protein drugs are notoriously difficult to deliver orally â but scientists have developed a new type of oral capsule that could deliver insulin and other similar drugs.

Insulin 52

Insulin Scientist Development Protein 52

Pharmaceutical Technology

JANUARY 10, 2023

In addition, TrialNet data collected from more than 200,000 relatives of people with T1D over the past two decades led to the research on defining the stages of T1D , making it possible to identify who will develop the disease and to advance prevention research. Developing sufficient testing infrastructure.

Insulin 246

Insulin FDA Approval Research Development 246

Drug Channels

JANUARY 9, 2024

There are also unusual formulary developments for insulin products, many of which experienced massive list price cuts for 2024. Unfortunately, the gross-to-net bubble will remain a fixture for this category, despite a price war led by almost half of the biosimilars. Read on for my deep dive into these two therapeutic categories.

Insulin 98

Insulin Pharmacy Drugs Production 98

pharmaphorum

OCTOBER 4, 2022

Danish company Novo Nordisk have announced positive results from the ONWARDS 5 phase 3 trial, with once-weekly insulin icodec demonstrating superior reduction of HbA1 in people with type 2 diabetes, in combination with a dosing guide app. ONWARDS 6 is to assess the efficacy and safety of insulin icodec in 583 people with type 1 diabetes.

Insulin 59

Insulin Trials Clinical Trials Clinical Trials 59

XTalks

AUGUST 29, 2024

The recent US Food and Drug Administration (FDA) clearance of the Omnipod 5 Automated Insulin Delivery (AID) System for people with type 2 diabetes marks a significant milestone in diabetes care. The Omnipod 5 system offers a personalized approach to insulin delivery, integrating CGM with adaptive insulin administration.

Insulin 59

Insulin Branding Development Drugs 59

Pharmaceutical Technology

JULY 12, 2022

VX-880 is an investigational allogeneic stem cell-derived, fully differentiated, insulin-producing islet cell therapy of Vertex for T1D. Through the acquisition, Vertex plans to advance its potentially curative VX-880 programmes in T1D. Subject to necessary conditions, the transaction is anticipated to conclude later this year.

Gene Therapy 276

Gene Therapy Insulin Manufacturing Clinical Trials 276

BioSpace

JULY 13, 2021

No specific financial details were disclosed other than to say the $1 billion figure was linked to various development and commercial milestones.

Insulin 101

Insulin Development 101

Scienmag

MAY 17, 2022

Well known for their applications in the production of therapeutic proteins like insulin, plasmids are broadly used in the large-scale production of many bioproducts. These small, circular DNA molecules are used by scientists to introduce new genes into a target organism. Credit: CABBI Plasmids have extensive […].

Production 90

Production Insulin Development DNA 90

Pharmaceutical Technology

MARCH 23, 2023

Scientific research and a better understanding of the condition is driving new developments in medications. The condition’s symptoms are not homogeneous, and that makes drug development complicated,” Javier Szwarcberg, CEO of Spruce Biosciences, a rare disease company researching endocrine disorders, says.

Development 130

Development Insulin Hormones Research 130

XTalks

AUGUST 13, 2024

Abbott and Medtronic have struck a global partnership to make diabetes management easier for people who need regular insulin injections. Abbott’s CGM sensors will work with Medtronic’s AID algorithms to automatically adjust insulin levels based on real-time blood sugar readings. billion by 2033.

Insulin 52

Insulin FDA Approval Marketing Development 52

Pharmaceutical Technology

MARCH 28, 2023

Vertex Pharmaceuticals has signed a new non-exclusive licensing agreement with CRISPR Therapeutics to expedite the development of its hypoimmune cell therapies to treat type 1 diabetes (T1D). The gene-editing technology allows for precise, directed changes to genomic DNA.

Gene Editing 235

Gene Editing DNA Gene Gene Therapy 235

Scienmag

SEPTEMBER 29, 2021

Pancreatic beta cells produce, store and secrete insulin upon elevated blood glucose levels. However, the highly regulated process of insulin secretion, especially its molecular features and the stimuli behind this process have not yet been fully understood.

In-Vivo 52

In-Vivo Insulin Development Regulation 52

pharmaphorum

MARCH 2, 2022

Novo Nordisk has made its smart insulin pens available in the UK, giving people treated within the NHS for diabetes access to devices that can monitor and record dosing information for the first time. Smart insulin pens are expected to drive the insulin pen market from $13.8

Insulin 52

Insulin Marketing Doctors Doctor 52

The Pharma Data

APRIL 28, 2022

Novo Nordisk today announced headline results from the ONWARDS 2 trial, a phase 3a, 26-week efficacy and safety treat-to-target trial investigating once-weekly insulin icodec vs insulin degludec in 526 people with type 2 diabetes switching from daily insulin. events per patient year exposed to once-weekly insulin icodec and 0.27

Insulin 52

Insulin Trials Clinical Trials Clinical Trials 52

Scienmag

NOVEMBER 9, 2021

A spectrum of conditions that includes coronary heart disease and diabetes, cardiometabolic disease typically impacts people who are obese, elderly, or insulin resistant. Decades after battling childhood cancer, survivors often face a new challenge: cardiometabolic disease. Credit: Laboratory of Molecular […].

Insulin 83

Insulin Development Medicine 83

BioPharma Reporter

SEPTEMBER 12, 2024

New data from the QWINT clinical trial may get Eli Lilly closer to bringing a once-weekly insulin injection to the US, following the FDAâs rejection of Novo Nordiskâs own weekly insulin formulation earlier this year.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

Drug Patent Watch

JANUARY 13, 2025

.” Diabetes: Addressing a Global Epidemic With diabetes affecting millions worldwide, the advent of biosimilar insulins has been particularly impactful. Tailored Education Programs: Empowering Patients and Providers Developing targeted education initiatives for different patient populations and healthcare specialties is crucial.

Marketing 78

Marketing Insulin Generic Drugs Medicine 78

BioSpace

JULY 12, 2022

A multinational research collaboration has developed a new peptide dubbed “PATAS”, which appears to fix the metabolic abnormalities leading to type 2 diabetes (T2D).

Insulin 90

Insulin Development Research 90

XTalks

FEBRUARY 24, 2021

The injection experience is an often-overlooked aspect in insulin administration. For many daily insulin users, the experience is an important one, as it is directly related to quality of life and medication compliance. Related: Droplet Micron Insulin Needle Offers Innovation in Crowded Diabetes Supply Market.

Insulin 64

Insulin Production Drug Delivery Marketing 64

XTalks

OCTOBER 13, 2021

Researchers at the University of Toledo have developed a vaccine against inflammatory arthritis that has shown promise in animal models. The potential cybersecurity risk associated with the remote controllers could under- or over-deliver insulin to patients if an unauthorized user hacks into the system.

Insulin 45

Insulin Life Science Vaccination Vaccine 45

pharmaphorum

SEPTEMBER 22, 2022

Insulin has been used to manage diabetes for a century, and while many advances have been made for people with both type 1 and type 2 diabetes – many more continue to be made. The post How a once-weekly insulin could disrupt diabetes management – the pharmaphorum podcast appeared first on.

Insulin 52

Insulin Clinical Trials Clinical Trials Trials 52

STAT News

APRIL 5, 2023

Obesity and diabetes in mothers have traditionally been considered risk factors for the child to also develop obesity. But a new study suggests that more narrow measures of health during pregnancy could help better assess that risk.

Insulin 119

Insulin Development Research 119

pharmaphorum

AUGUST 20, 2024

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese adults with pre-diabetes.There's plenty of evidence to show that prediabetes – a higher-than-normal blood sugar level resulting from a level of insulin resistance (..)

Insulin 110

Insulin Trials Development Drugs 110

XTalks

NOVEMBER 2, 2021

The government of Scotland has rolled out a new C-peptide test for type 1 diabetes that could help patients monitor their insulin levels with greater accuracy. The test provides information about the amount of insulin a patient has in their body, which can help determine whether they can reduce or stop taking their insulin injections.

Insulin 98

Insulin Protein Hormones Regulation 98